Jaguar Health Inc (JAGX) News & EventsJAGXNews & EventsJaguar Health Inc

Jaguar Health Launches Commercial Product Neonorm Dog

Jaguar Health announced the initiation of the commercial launch of Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion and production animals. "Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool consistency and GI fluid balance in dogs," the company said.

Jaguar Health Meets Conditions for $2M Payment

Jaguar Health announced that its wholly-owned subsidiary Napo Pharmaceuticals has satisfied the conditions required to receive payment of the non-dilutive $2M holdback amount from Future Pak related to the U.S. commercial licensing agreement Jaguar entered in January 2026 with a Future Pak affiliate. As announced, Jaguar was provided with a partial upfront fee of $16M of non-dilutive capital upon closing of the agreement. Per the terms of the agreement, the additional $2M portion of the upfront fee is due to Jaguar upon Jaguar's completion of specified post-closing conditions, which the company has met.

Jaguar Health Supports Commercial Opportunity for Neonorm Dog

Jaguar Health announced that the findings of exploratory surveys of dog owners and veterinary oncologists support the company's commercial opportunity for Neonorm Dog, a new extension of Jaguar's Neonorm franchise for companion animals. Neonorm Dog is designed to provide dog owners with access to a plant-based, non-prescription product intended to support normal stool consistency and GI fluid balance in dogs. "The results of our directional survey of 33 veterinary oncologists reinforce our belief that there is a meaningful unmet need for additional non-antibiotic, locally acting digestive support options for dogs with loose or watery stool that are designed to help support normal stool consistency and complement supportive care" said Ian Wendt, Jaguar's Chief Business Officer. "It is encouraging that nearly 90% of responding veterinary oncology specialists viewed the Neonorm Dog concept as clinically relevant, and that almost 80% indicated they would be likely to recommend it for selected canine oncology patients if available. 69% say they would be somewhat or very likely to recommend that dog owners keep Neonorm Dog at home for early loose stool. We view this feedback as important guidance as we continue preparing for our planned launch of Neonorm Dog."